Inhibikase Therapeutics (NASDAQ: IKT)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-15 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.170 | -0.180 | -0.0100 | ||||
REV | 300.000K | 46.031K | -253.969K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Inhibikase Therapeutics (NASDAQ: IKT) through any online brokerage.
There are no as such competitors for Inhibikase Therapeutics.
The latest price target for Inhibikase Therapeutics (NASDAQ: IKT) was reported by JonesTrading on Thursday, July 15, 2021. The analyst firm set a price target for 12.00 expecting IKT to rise to within 12 months (a possible 1664.71% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Inhibikase Therapeutics (NASDAQ: IKT) is $0.68 last updated Today at May 17, 2022, 1:57 PM UTC.
There are no upcoming dividends for Inhibikase Therapeutics.
Inhibikase Therapeutics’s Q2 earnings are confirmed for Monday, August 15, 2022.
There is no upcoming split for Inhibikase Therapeutics.
Inhibikase Therapeutics is in the Healthcare sector and Biotechnology industry. They are listed on the NASDAQ.